Yantai Lannacheng Biotechnology Co., Ltd.

烟台蓝纳成生物技术股份有限公司

Clinical-stage biotechnology company developing diagnostic and therapeutic radiopharmaceuticals for oncology, with a pipeline of 13 candidates including a registrational-stage PET imaging agent for PSMA-positive prostate cancer, based in China.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Supplier concentration
• Outsourced production (OEM / contract manufacturing)
• Reliance on the controlling shareholder
• Losses and path to profitability
• Negative operating cash flow
• Cash burn and runway
• Goodwill, intangibles and asset impairment
• Related-party transactions and balances
• Chapter 18A biotech